Details of the Drug Reposition

General Information of This Drug (ID: DM6DK9A)

Drug Name
PVX-410   DM6DK9A

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple myeloma DISEWP9B 2A83 Phase 2 [1]
Triple negative breast cancer DISAMG6N 2C60-2C65 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT04634747) A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembrolizumab + Chemotherapy for Frontline Therapy of Metastatic, PD-L1+ Triple-Negative Breast Cancer (TNBC) in HLA-A2-Positive Patients. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT01718899) Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma. U.S. National Institutes of Health.